查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010047

癌症疫苗市場：2026-2032年全球市場預測（依產品類型、劑型、給藥途徑、研發階段、適應症及最終用戶分類）

Cancer Vaccines Market by Product Type, Formulations, Administration Pathway, Development Phase, Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症疫苗市場價值將達到 77.8 億美元，到 2026 年將成長至 85.3 億美元，到 2032 年將達到 150.8 億美元，複合年成長率為 9.90%。

主要市場統計數據
基準年 2025 77.8億美元
預計年份：2026年 85.3億美元
預測年份 2032 150.8億美元
複合年成長率 (%) 9.90%

簡要概述正在重塑癌症疫苗研發和相關人員決策的科學、臨床和商業性因素的融合。

癌症疫苗領域正處於關鍵的轉折點，這得益於數十年的免疫學研究、分子生物學的進步以及基於免疫的腫瘤解決方案的商業性化復甦。本執行摘要整合了塑造該領域的核心趨勢，概述了新型抗原發現、遞送平台和轉化科學如何融合，從而重新定義惡性腫瘤的治療和預防方法。透過重點介紹創新促進因素、不斷變化的監管以及臨床應用中的瓶頸，本導言為後續的詳細分析章節奠定了基礎。

平台成熟度、與適應性強的監管機構的合作以及策略夥伴關係正在從根本上改變發展路徑和競爭優勢的動態。

過去幾年，癌症疫苗領域經歷了翻天覆地的變化，涵蓋了從零星的科學突破到平台演進、監管調整以及產業策略重組等各個面向。首先，核酸平台的成熟加速了原型疫苗的研發，並簡化了疫苗的迭代設計。因此，研發人員目前正致力於採用混合策略，將現成的組件與個人化的新抗原有效載荷相結合，從而改變了專案設計和臨床開發的週期。

本研究評估了 2025 年關稅變化和貿易政策轉變將如何影響整個疫苗生態系統的採購、製造韌性和臨床試驗物流。

2025年關稅的實施和貿易政策調整對支持癌症疫苗研發和商業化的全球供應鏈產生了複雜的影響。由於關稅導致試劑、一次性塑膠和某些生物製程組件的投入成本增加，促使籌資策略改變，迫使贊助商重新評估供應商多元化和近岸外包方案。因此，各組織必須在成本控制和維持高品質、合規的供應鏈之間取得平衡，以確保其敏感的生技藥品務順利進行。

分析多方面的細分，並在涵蓋適應症和醫療保健環境的差異化疫苗項目中，協調配方、臨床策略和醫療保健服務。

細分市場層面的趨勢揭示了不同的需求和機遇，這有助於制定產品策略、臨床設計和市場推廣計劃。根據產品類型，該領域可分為預防性癌症疫苗和治療性癌症疫苗，二者針對不同的目標族群、監管管道和商業性價值提案。預防性疫苗需要廣泛的安全性和長期監測系統，而治療性疫苗則強調腫瘤特異性免疫抗原性和聯合治療以達到持續療效。

全球範圍內監管差異、臨床能力和生產能力如何影響研發重點和打入市場策略？

區域趨勢對整個癌症疫苗領域的研發重點、監管互動和商業化規劃都產生顯著影響。在美洲，活躍的創業投資活動、先進的臨床試驗基礎設施和成熟的生物製造網路為快速迭代研發和早期人體試驗提供了支援。因此，申辦方通常會優先考慮在這些市場進行「首次人體試驗」並積極與監管機構溝通，以降低科學風險並確保早期臨床療效。

對決定該領域競爭差異化和合作夥伴關係吸引力的策略經營模式、夥伴關係動態和營運能力進行評估。

癌症疫苗領域的企業策略呈現出多元化的模式，涵蓋了從垂直整合的創新企業到專業技術提供者和生產合作夥伴等各個方面。生技公司致力於打造差異化平台，專注於發展其專有的抗原發現引擎；而大型製藥企業則日益關注將疫苗整合到聯合治療中，以充分利用其現有的癌症治療產品組合。在整個生態系統中，策略聯盟、許可協議和共同開發契約是獲取互補能力和縮短臨床試驗時間的關鍵機制。

生物製藥公司領導者可以採取切實可行的、以里程碑為基礎的步驟來降低專案風險、加速臨床應用並增強與支付者和合作夥伴的議價能力。

領先機構需要採取實際有效的措施，將科學潛力轉化為永續的臨床和商業性成果。首先，應優先進行平台檢驗，透過精心設計的轉化研究，將基於機制的生物標記與有意義的臨床終點聯繫起來。這種方法可以降低後期試驗的退出率，並加強與監管機構和支付方的溝通。其次，應投資於靈活的生產結構和雙源採購策略，以降低供應鏈風險，並快速應對專案迭代調整。

透明、多方面的研究途徑結合了初步訪談、專家文獻和分析檢驗，為切實可行的實證建議提供了支持。

本研究採用混合方法，整合了第一手訪談、嚴謹的二手資料研究和分析三角驗證，以確保獲得可靠且可操作的見解。第一手資料研究包括對行業高管、臨床研究人員、生產專家和支付方顧問進行結構化訪談，以了解他們對營運限制、試驗設計偏好和商業性准入預期等方面的真實觀點。這些定性資料與公開的監管指南、同儕審查文獻和企業資訊披露相結合，從而全面了解產業動態。

將科學機會與實施要求結合，明確領導者應如何平衡創新、韌性和策略夥伴關係以取得成功。

總之，癌症疫苗領域瞬息萬變，科學創新、商業性機會和營運複雜性在此交匯融合。平台技術和轉化科學的進步拓寬了可能性，但要實現臨床和商業性的成功，需要在生產製造、監管策略和醫保支付方參與等方面進行嚴謹的執行。此外，貿易政策和供應鏈考量如今已成為研發計畫不可或缺的組成部分，我們鼓勵申辦方採用能夠兼顧多元化採購和地理因素的生產策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症疫苗市場：依產品類型分類

  • 預防性癌症疫苗
  • 用於治療的癌症疫苗

第9章 癌症疫苗市場（依製劑類型分類）

  • 細胞疫苗
    • 樹突細胞疫苗
    • 癌細胞疫苗
  • 核酸疫苗
    • DNA疫苗
    • RNA疫苗
  • 胜肽/蛋白質疫苗
  • 合成疫苗
  • 病毒載體疫苗

第10章：癌症疫苗市場依給藥途徑分類

  • 肌肉內部
  • 靜脈

第11章：癌症疫苗市場依研發階段分類

  • 臨床試驗
  • 第一階段
  • 第二階段
  • 第三階段

第12章：癌症疫苗市場：依適應症分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 惡性黑色素瘤
  • 攝護腺癌

第13章：癌症疫苗市場：依最終用戶分類

  • 癌症研究機構
  • 醫院和診所
  • 癌症治療中心

第14章 癌症疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：癌症疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 癌症疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國癌症疫苗市場

第18章：中國癌症疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advaxis Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • CureVac SE
  • Dynavax Technologies Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GSK PLC
  • Helsinn Healthcare SA
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc
  • JW CreaGene
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Sanpower Group Co., Ltd.
  • Scorpius Holdings, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Vaxine Pty Ltd
Product Code: MRR-434CCDA0514B

The Cancer Vaccines Market was valued at USD 7.78 billion in 2025 and is projected to grow to USD 8.53 billion in 2026, with a CAGR of 9.90%, reaching USD 15.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.78 billion
Estimated Year [2026] USD 8.53 billion
Forecast Year [2032] USD 15.08 billion
CAGR (%) 9.90%

A concise orientation to the scientific, clinical, and commercial forces converging to reshape cancer vaccine development and stakeholder decision-making

The field of cancer vaccines is at a pivotal inflection point driven by decades of immunology research, advances in molecular biology, and renewed commercial interest in immune-based oncology solutions. This executive summary synthesizes core dynamics shaping the sector, framing how novel antigen discovery, delivery platforms, and translational science converge to redefine therapeutic and preventive approaches to malignancies. By clarifying the drivers of innovation, regulatory evolution, and clinical translation bottlenecks, this introduction sets context for the deeper analytical sections that follow.

Importantly, the landscape combines established scientific principles with rapid technological iteration, meaning that incremental improvements in vaccine design can yield outsized clinical and operational benefits. As such, stakeholders must view scientific breakthroughs alongside commercialization realities including manufacturing complexity, supply chain resilience, and reimbursement environments. Moving forward, this report adopts an integrated lens that links scientific promise to practical execution, enabling decision-makers to prioritize investments that balance near-term clinical feasibility with longer-term strategic differentiation.

How platform maturation, adaptive regulatory engagement, and strategic alliances are fundamentally altering development pathways and competitive advantage dynamics

Over the past several years the cancer vaccine landscape has undergone transformative shifts that extend beyond isolated scientific breakthroughs to encompass platform evolution, regulatory recalibration, and strategic industry realignment. First, the maturation of nucleic acid platforms has accelerated iterative vaccine designs that are faster to prototype and easier to personalize. Consequently, developers now pursue hybrid strategies that combine off-the-shelf components with individualized neoantigen payloads, driving a shift in program design and clinical development timelines.

Concurrently, manufacturing innovations and the rise of experienced contract development and manufacturing organizations have altered capacity planning and lowered some barriers to scale. In parallel, regulators have signaled a willingness to engage early on platform-specific endpoints and adaptive trial designs, which has encouraged sponsors to pursue pragmatic pathways to demonstrate clinical benefit. At the same time, commercial strategies have shifted from single-product plays to ecosystem-focused approaches that pair vaccines with companion diagnostics, checkpoint inhibitors, or radiotherapy to enhance response durability.

These combined shifts mean that competitive advantage will increasingly accrue to organizations that can integrate rapid antigen discovery, flexible manufacturing, and robust translational biomarker programs. As a result, partnerships and strategic alliances are becoming a primary vehicle for accelerating development while distributing risk across specialized collaborators.

Assessing how tariff shifts and trade policy changes in 2025 are reshaping procurement, manufacturing resilience, and clinical trial logistics across the vaccine ecosystem

The imposition of tariffs and trade policy adjustments in 2025 introduced a complex overlay on the global supply chains that underpin cancer vaccine research, development, and commercialization. Tariff-driven increases in input costs for reagents, single-use plastics, and certain bioprocessing components have altered procurement strategies and prompted sponsors to re-evaluate supplier diversification and nearshoring options. In turn, organizations must reconcile the tension between cost management and the necessity of maintaining high-quality, compliant supply chains for sensitive biologics work.

Moreover, tariffs have affected cross-border movement of clinical trial materials and investigational products, adding administrative complexity and potential delays in multinational study execution. Consequently, trial sponsors are adjusting logistics planning, expanding buffer stocks, and engaging earlier with customs and regulatory stakeholders to minimize disruption. In addition, the cumulative policy environment has influenced investor sentiment and capital allocation decisions, particularly for early-stage companies that rely on international partnerships for manufacturing or distribution.

From a strategic standpoint, the most resilient organizations respond by mapping critical suppliers, identifying substitute inputs, and negotiating longer-term procurement agreements. At the same time, decision-makers are evaluating investments in regional manufacturing capacity and collaborative consortia that spread tariff exposure while preserving the agility required for iterative vaccine development.

Interpreting multi-dimensional segmentation to align formulation, clinical strategy, and care delivery for differentiated vaccine programs across indications and settings

Segment-level dynamics reveal differentiated needs and opportunities that inform product strategy, clinical design, and go-to-market planning. Based on product type, the field separates into preventive cancer vaccines and therapeutic cancer vaccines, each with distinct target populations, regulatory pathways, and commercial value propositions. Preventive approaches necessitate broad safety and long-term surveillance frameworks, whereas therapeutic vaccines emphasize tumor-specific immunogenicity and combination regimens to achieve durable responses.

Based on formulations, developers are advancing multiple modalities including cell-based vaccines, nucleic acid-based vaccines, peptide and protein constructs, synthetic vaccines, and viral vector systems. Within cell-based approaches, dendritic cell vaccines and tumor cell vaccines offer different manufacturing complexity and personalization trade-offs. Similarly, nucleic acid-based platforms differentiate into DNA vaccines and RNA vaccines, with each presenting unique delivery and stability considerations that affect clinical deployment.

Based on administration pathway, studies and clinical operations focus on intramuscular and intravenous delivery routes, choices that influence patient experience, pharmacokinetics, and site-of-care logistics. Based on development phase, programs span clinical trials across Phase I, Phase II, and Phase III, shaping evidence requirements and regulatory engagement strategies. Based on indication, teams prioritize target malignancies such as breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer, each of which imposes distinct biomarker, endpoint, and competitive considerations. Based on end-user, adoption pathways vary across cancer research institutes, hospitals and clinics, and specialty cancer treatment centers, factors that inform commercialization and reimbursement planning.

Taken together, these segmentation lenses illustrate that no single development path fits all programs; instead, sponsors must align formulation, delivery, and clinical strategy to the indication, patient population, and intended care setting to optimize chances of successful translation.

How regional regulatory nuance, clinical capacity, and manufacturing capabilities across global regions shape development priorities and market entry strategies

Regional dynamics significantly influence development priorities, regulatory engagement, and commercial planning across the cancer vaccine landscape. In the Americas, strong venture capital activity, advanced clinical trial infrastructure, and established biomanufacturing networks support rapid iteration and early human testing. Consequently, sponsors often prioritize first-in-human studies and regulatory interactions in these markets to de-risk science and secure early clinical validation.

In Europe, Middle East & Africa, diverse regulatory frameworks and varying reimbursement pathways require tailored evidence generation strategies, while the region's strong academic networks and collaborative research consortia provide fertile ground for translational science and investigator-initiated trials. Stakeholders operating in this region often engage early with regional regulators and payers to harmonize clinical endpoints and access pathways.

In the Asia-Pacific region, accelerating public and private investment in biotechnology, expanding manufacturing capacity, and growing patient populations create opportunities for large-scale studies and regional manufacturing partnerships. However, developers must navigate heterogeneous regulatory timelines and local clinical practice patterns. Across all regions, successful strategies combine global program design with regional execution plans that account for regulatory nuance, supply chain considerations, and local stakeholder engagement to enable efficient development and market entry.

Evaluating strategic business models, partnership dynamics, and operational capabilities that determine competitive differentiation and partnership appeal in the sector

Company strategies in the cancer vaccine sector reflect a spectrum of models that range from vertically integrated innovators to specialized technology providers and manufacturing partners. Biotech companies pursue differentiated platforms with an emphasis on proprietary antigen discovery engines, while larger pharmaceutical firms are increasingly focused on integrating vaccines into combination regimens that leverage their existing oncology portfolios. Across the ecosystem, strategic collaborations, licensing agreements, and co-development arrangements serve as primary mechanisms to obtain complementary capabilities and accelerate time to clinic.

Notably, contract development and manufacturing organizations play a pivotal role by enabling smaller developers to access GMP-compliant production and scale-up expertise without the capital intensity of building internal capacity. In addition, diagnostic developers and biomarker companies are becoming essential allies, providing the companion tools needed to select patients and measure pharmacodynamic responses. Investors and corporate development teams are therefore evaluating partner fit across technical proficiency, regulatory experience, and cultural alignment to manage program risk.

Ultimately, competitive differentiation will depend on the ability to combine scientific novelty with operational excellence, regulatory foresight, and reimbursement strategy. Companies that can demonstrate reproducible manufacturing, robust translational datasets, and clear paths to payer evidence will command strategic advantage in partnerships and capital markets.

Practical, milestone-driven steps that biopharma leaders can implement to de-risk programs, accelerate clinical translation, and strengthen payer and partner negotiations

Leading organizations must adopt pragmatic, high-impact actions to translate scientific potential into durable clinical and commercial outcomes. First, prioritize platform validation through well-designed translational studies that link mechanistic biomarkers to meaningful clinical endpoints; this approach reduces late-stage attrition and strengthens conversations with regulators and payers. Next, invest in flexible manufacturing arrangements and dual-sourcing strategies to mitigate supply chain risk and respond quickly to iterative program adjustments.

Additionally, pursue strategic collaborations that align scientific synergies with operational needs, such as partnering with diagnostic developers to co-develop companion assays or engaging experienced CDMOs to accelerate GMP manufacturing timelines. Further, adopt adaptive clinical trial designs and real-world evidence collection strategies to generate robust datasets that support both regulatory submissions and payer negotiations. From a commercial perspective, refine value propositions by mapping patient pathways and stakeholder economics to ensure pricing and access strategies reflect clinical differentiation and real-world impact.

Finally, build internal capabilities in regulatory strategy, health economics and outcomes research, and manufacturing science to reduce dependence on external partners and to retain negotiating leverage. By sequencing these actions and establishing clear milestone-based decision gates, leaders can preserve optionality while accelerating programs that demonstrate the highest probability of clinical and commercial success.

A transparent, multi-source research approach combining primary interviews, technical literature, and analytical validation to underpin practical, evidence-based recommendations

This research employs a mixed-methods approach that integrates primary interviews, rigorous secondary research, and analytical triangulation to ensure robust and actionable findings. Primary research included structured interviews with industry executives, clinical investigators, manufacturing experts, and payer advisors to capture real-world perspectives on operational constraints, trial design preferences, and commercial access expectations. These qualitative inputs were synthesized with publicly available regulatory guidance, peer-reviewed literature, and company disclosures to construct a comprehensive understanding of sector dynamics.

Secondary research encompassed literature review, analysis of clinical trial registries, and technical white papers that document platform performance, safety profiles, and biomarker strategies. The methodology also applied comparative analysis across regional regulatory frameworks and supply chain configurations to highlight executional risks and opportunities. Analytical validation steps included cross-checking interview insights against documented trial outcomes and manufacturing case studies, and conducting scenario analysis to explore policy and operational contingencies.

Limitations of the approach are acknowledged; for instance, proprietary internal data from private firms may not be fully accessible, and rapidly evolving trial outcomes can shift competitive positions. Nevertheless, the triangulated methodology provides a defensible basis for strategic recommendations and enables stakeholders to tailor the insights to their specific portfolio and risk appetite.

A synthesis of scientific opportunity and executional requirements that clarifies how leaders must balance innovation, resilience, and strategic partnerships to succeed

In conclusion, cancer vaccines occupy a dynamic intersection of scientific innovation, commercial opportunity, and operational complexity. Advances in platform technologies and translational science have expanded the realm of possibility, but realizing clinical and commercial impact requires disciplined execution across manufacturing, regulatory strategy, and payer engagement. Moreover, trade policy and supply chain considerations are now integral to development planning, motivating sponsors to adopt diversified sourcing and geographically informed manufacturing strategies.

Going forward, organizations that integrate rigorous biomarker-driven program designs with flexible manufacturing and strategic partnerships will be best positioned to navigate the competitive environment. Strategic patience, combined with targeted investments in clinical validation and operational resilience, will enable sponsors to convert scientific promise into patient benefit. Ultimately, the path to success is multifaceted and demands that scientific ambition be matched by pragmatic, well-resourced execution across the entire product lifecycle.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Vaccines Market, by Product Type

  • 8.1. Preventive Cancer Vaccines
  • 8.2. Therapeutic Cancer Vaccines

9. Cancer Vaccines Market, by Formulations

  • 9.1. Cell-Based Vaccines
    • 9.1.1. Dendritic Cell Vaccines
    • 9.1.2. Tumor Cell Vaccines
  • 9.2. Nucleic Acid-Based Vaccines
    • 9.2.1. DNA Vaccines
    • 9.2.2. RNA Vaccines
  • 9.3. Peptide/Protein-Based Vaccines
  • 9.4. Synthetic Vaccines
  • 9.5. Viral Vector-Based Vaccines

10. Cancer Vaccines Market, by Administration Pathway

  • 10.1. Intramuscular
  • 10.2. Intravenous

11. Cancer Vaccines Market, by Development Phase

  • 11.1. Clinical Trials
  • 11.2. Phase I
  • 11.3. Phase II
  • 11.4. Phase III

12. Cancer Vaccines Market, by Indication

  • 12.1. Breast Cancer
  • 12.2. Colorectal Cancer
  • 12.3. Lung Cancer
  • 12.4. Melanoma
  • 12.5. Prostate Cancer

13. Cancer Vaccines Market, by End-User

  • 13.1. Cancer Research Institutes
  • 13.2. Hospitals & Clinics
  • 13.3. Specialty Cancer Treatment Centers

14. Cancer Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Vaccines Market

18. China Cancer Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Advaxis Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca PLC
  • 19.8. Bayer AG
  • 19.9. BioNTech SE
  • 19.10. Bristol Myers Squibb Company
  • 19.11. Celldex Therapeutics, Inc.
  • 19.12. CureVac SE
  • 19.13. Dynavax Technologies Corporation
  • 19.14. Eli Lilly and Company
  • 19.15. F. Hoffmann-La Roche AG
  • 19.16. GSK PLC
  • 19.17. Helsinn Healthcare SA
  • 19.18. Inovio Pharmaceuticals, Inc.
  • 19.19. Johnson & Johnson Services, Inc
  • 19.20. JW CreaGene
  • 19.21. Merck & Co., Inc.
  • 19.22. Moderna, Inc.
  • 19.23. Pfizer Inc.
  • 19.24. Sanofi SA
  • 19.25. Sanpower Group Co., Ltd.
  • 19.26. Scorpius Holdings, Inc.
  • 19.27. Serum Institute of India Pvt. Ltd.
  • 19.28. Sun Pharmaceutical Industries Ltd.
  • 19.29. Vaxine Pty Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER VACCINES MARKET SIZE, BY TUMOR CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER VACCINES MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER VACCINES MARKET SIZE, BY RNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER VACCINES MARKET SIZE, BY PEPTIDE/PROTEIN-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER VACCINES MARKET SIZE, BY SYNTHETIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR-BASED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER VACCINES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER VACCINES MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER VACCINES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER VACCINES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER VACCINES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER VACCINES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER VACCINES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER VACCINES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER VACCINES MARKET SIZE, BY SPECIALTY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS CANCER VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. GCC CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 173. GCC CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 200. G7 CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. NATO CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 209. NATO CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CANCER VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CANCER VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CANCER VACCINES MARKET SIZE, BY FORMULATIONS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA CANCER VACCINES MARKET SIZE, BY CELL-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA CANCER VACCINES MARKET SIZE, BY NUCLEIC ACID-BASED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA CANCER VACCINES MARKET SIZE, BY ADMINISTRATION PATHWAY, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CANCER VACCINES MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CANCER VACCINES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CANCER VACCINES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)